TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05418387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Network Intervention
Description: The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (Patient Navigation Service)
Description: The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
Study: NCT06425419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
Study: NCT05926297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application NaOCl gel + HA gel
Description: First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical debridement
Description: Only mechanical debridement with curettes ans scaler tips
Study: NCT06222723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
Study: NCT05083559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC AP algorithm
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robust R-AP algorithm
Description: The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
Study: NCT05925049

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study: NCT05533112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Stimulation
Description: During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Stimulation
Description: During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Stimulation
Description: During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
Study: NCT04904978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blanx Black Toothpaste
Description: Use of Blanx Black Toothpaste twice a day per at least 2 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Sensation White
Description: Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
Study: NCT05945849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33KO-HSPC; CART33
Description: CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells.
Study: NCT05153590

Intervention type: DRUG
Intervention: Saxenda®
Description: Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.

Intervention type: DRUG
Intervention: Saxenda®
Description: Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.
Study: NCT05115955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS group
Description: In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
Study: NCT05357261

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Check and Socialization
Description: In-home delivery with opportunity for driver observation and interaction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prepared Meals
Description: Prepared meals compliant with Older Americans Act nutrition programs guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prepared Meals
Description: Prepared meals compliant with Older Americans Act nutrition programs guidelines
Study: NCT06228053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: Specified dose twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Specified dose once daily
Study: NCT05580588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336
Description: 400 mg SPH4336 PO QD
Study: NCT05197881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Ethos Adaptive Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study: NCT05166512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Cooks
Description: 6 'food agency' based cooking skills classes during the first 4 months of the DPP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP
Description: Standard DPP
Study: NCT05558189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset (vCR)
Description: The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
Study: NCT05482893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT886
Description: PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT886
Description: PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT886
Description: PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT886
Description: PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy as a combination partner to PT886 in Part C: Cohort 1
Study: NCT06213597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine swallowing rehabilitation
Description: Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: routine swallowing rehabilitation
Description: Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real repetitive transcranial magnetic stimulation
Description: In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
Study: NCT05482893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy as a combination partner to Abraxane and PT886 in Part C: Cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy as a combination partner to Gemcitabine and PT886 in Part C: Cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: Immune checkpoint inhibitor as a combination partner to PT886 in Part D: Cohort 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
Study: NCT04372615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inebilizumab
Description: RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive IV matching placebo on Day 1 and Day 15,
Study: NCT05482893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Chemotherapy as a combination partner to PT886 in Part C: Cohort 2b
Study: NCT05255783

Intervention type: DEVICE
Group type: OTHER
Intervention: subcutaneous continuous glucose sensor
Description: Dexcom G6 continuous glucose monitoring system
Study: NCT05733429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery therapy
Description: the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
Study: NCT06472050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: osteoporosis treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: osteoporosis treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: osteoporosis treatment
Study: NCT05789420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes
Study: NCT05587686

Intervention type: OTHER
Intervention: VentilO application
Description: This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings.
Study: NCT05733429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
Study: NCT06216275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Snoezelen-Aromatherapy-Personal Item Therapy
Description: Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized
Study: NCT05317000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 5-azacytidine and nivolumab
Description: The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-azacytidine
Description: Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells.
Study: NCT05565872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban training
Description: A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urban training
Description: A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
Study: NCT01691261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05206388
Description: PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.